Skip to content
Research Article Open access CC BY 4.0

Recent Approaches of Drugs and Vaccines Used in COVID 19: A Review

S. Sivakumar, K. Kathiresan, P. Pandian

Journal of Pharmaceutical Research International · pp. 1–10 · Published 10 Mar 2022

10.9734/jpri/2022/v34i22A35848

Abstract

A novel SARS-CoV-2 coronavirus developed in December 2019, triggering a life-threatening pneumonia outbreak in China, and has since expanded worldwide, producing a pandemic. Because of the urgent need to control the disease and the dearth of specific and effective treatment options, FDA-approved medicines that have proven efficacy against comparable viruses are being used. In vitro, chloroquine, remdesivir, lopinavir/ritonavir or ribavirin are effective at inhibiting SARS-CoV-2. The preliminary findings of a variety of clinical trials utilising various chloroquine or hydroxychloroquine delivery procedures all indicate a positive outcome. They may not be effective in cases of consistently high viremia, and data on ivermectin (another antiparasitic medication) is currently unavailable. Intriguingly, azithromycin, a macrolide antibiotic, in conjunction with hydroxychloroquine may provide therapeutic benefits. Favipiravir, tocilizumab, and azithromycin types are among the other treatment options being investigated.

SARS-CoV 2 MOA drugs vaccines

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

1

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.